Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints

被引:5
作者
Martinez, Jordi Cortes [1 ]
Geskus, Ronald B. [2 ,3 ]
Kim, Kyung Mann [4 ]
Melis, Guadalupe Gomez [1 ]
机构
[1] Univ Politecn Cataluna, Dept Stat & Operat Res, Jordi Girona 31, Barcelona 08034, Spain
[2] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam
[3] Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England
[4] Univ Wisconsin, Dept Biostat & Med Informat, 600 Highland Ave, Madison, WI 53792 USA
基金
英国惠康基金;
关键词
Treatment Effect; Composite endpoint; Randomized Controlled Trial; Progression-Free Survival; Simulation; Copula; Non-Proportional Hazards; DOUBLE-BLIND; SURVIVAL;
D O I
10.1186/s12874-021-01286-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Sample size calculation is a key point in the design of a randomized controlled trial. With time-to-event outcomes, it's often based on the logrank test. We provide a sample size calculation method for a composite endpoint (CE) based on the geometric average hazard ratio (gAHR) in case the proportional hazards assumption can be assumed to hold for the components, but not for the CE. Methods The required number of events, sample size and power formulae are based on the non-centrality parameter of the logrank test under the alternative hypothesis which is a function of the gAHR. We use the web platform, CompARE, for the sample size computations. A simulation study evaluates the empirical power of the logrank test for the CE based on the sample size in terms of the gAHR. We consider different values of the component hazard ratios, the probabilities of observing the events in the control group and the degrees of association between the components. We illustrate the sample size computations using two published randomized controlled trials. Their primary CEs are, respectively, progression-free survival (time to progression of disease or death) and the composite of bacteriologically confirmed treatment failure or Staphylococcus aureus related death by 12 weeks. Results For a target power of 0.80, the simulation study provided mean (+/- SE) empirical powers equal to 0.799 (+/- 0.004) and 0.798 (+/- 0.004) in the exponential and non-exponential settings, respectively. The power was attained in more than 95% of the simulated scenarios and was always above 0.78, regardless of compliance with the proportional-hazard assumption. Conclusions The geometric average hazard ratio as an effect measure for a composite endpoint has a meaningful interpretation in the case of non-proportional hazards. Furthermore it is the natural effect measure when using the logrank test to compare the hazard rates of two groups and should be used instead of the standard hazard ratio.
引用
收藏
页数:14
相关论文
共 50 条
[31]   Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint [J].
Rulli, Eliana ;
Ghilotti, Francesca ;
Biagioli, Elena ;
Porcu, Luca ;
Marabese, Mirko ;
D'Incalci, Maurizio ;
Bellocco, Rino ;
Torri, Valter .
BRITISH JOURNAL OF CANCER, 2018, 119 (12) :1456-1463
[32]   Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes [J].
Riley, Richard D. ;
Snell, Kym I. E. ;
Ensor, Joie ;
Burke, Danielle L. ;
Harrell, Frank E., Jr. ;
Moons, Karel G. M. ;
Collins, Gary S. .
STATISTICS IN MEDICINE, 2019, 38 (07) :1276-1296
[33]   Using Restricted Mean Survival Time to Improve Interpretability of Time-to-Event Data Analysis [J].
Charu, Vivek ;
Tian, Lu ;
Tamura, Manjula Kurella ;
Montez-Rath, Maria E. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 19 (02) :260-262
[34]   Exploring migration data using interval-censored time-to-event models [J].
Fieberg, John ;
Delgiudice, Glenn .
JOURNAL OF WILDLIFE MANAGEMENT, 2008, 72 (05) :1211-1219
[35]   Power and sample-size analysis for the Royston Parmar combined test in clinical trials with a time-to-event outcome: Correction and program update [J].
Royston, Patrick .
STATA JOURNAL, 2018, 18 (04) :995-996
[36]   The use of restricted cubic splines to approximate complex hazard functions in the analysis of time-to-event data: a simulation study [J].
Rutherford, Mark J. ;
Crowther, Michael J. ;
Lambert, Paul C. .
JOURNAL OF STATISTICAL COMPUTATION AND SIMULATION, 2015, 85 (04) :777-793
[37]   Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculation [J].
Tanase, Takanori .
PHARMACEUTICAL STATISTICS, 2020, 19 (02) :126-136
[38]   Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test [J].
Kwak, Minjung ;
Jung, Sin-Ho .
STATISTICS IN MEDICINE, 2014, 33 (12) :2004-2016
[39]   Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab [J].
Park, Suemin ;
Jung, Jin Ah ;
Ju, Sungil ;
Lim, Hyeong-Seok .
FRONTIERS IN PHARMACOLOGY, 2024, 14
[40]   Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data [J].
Le Coent, Quentin ;
Legrand, Catherine ;
Rondeau, Virginie .
BIOSTATISTICS, 2023, 25 (01) :98-116